Zoetis receives FDA approval for dog treatment: what it means for Zoetis stock - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
Zoetis Inc. (US98978V1035) received U.S. Food and Drug Administration approval on October 20, 2026, for Convenia RTU for Dogs, an injectable treatment that can provide up to 14 days of antibiotic therapy. The company is scheduled to report third-quarter results on November 5, 2026. According to Zoetis, Convenia RTU is intended for susceptible bacterial skin infections in dogs and is administered by a veterinary professional. The company expects the product to become available to veterinarians in the first quarter of 2027. The treatment extends the company's companion-animal product offering with a single-injection format for dogs of all sizes. That commercial angle matters as pricing power has become a central concern for the stock. On October 20, 2026, Jefferies downgraded Zoetis to Hold from Buy and cut its price target from USD 103 to USD 83, a 19.42 percent reduction, according to Markets Insider. The firm cited a softer pricing environment and limited visibility on future margin expansion. Zoetis declared a fourth-quarter 2026 dividend of USD 0.53 per share on October 8, 2026, according to Business Wire. It appointed Iris Knobloch to its board effective December 1, 2026, on October 13, 2026, as reported by Business Wire . The October 20 FDA approval is the latest of the three events. The dividend record and ex-dividend date is October 30, 2026, while the next...
Keep reading with a free account
The rest of this article, and every signal for Zoetis, is in your free account.
